Clodronate: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Drugbox | |||
| verifiedrevid = 476996903 | |||
| IUPAC_name = (dichloro-phosphono-methyl)phosphonic acid | |||
| image = Clodronic acid.png | |||
<!--Clinical data--> | |||
| tradename = | |||
| Drugs.com = {{drugs.com|international|clodronic-acid}} | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| pregnancy_US = <!-- A / B / C / D / X --> | |||
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> | |||
| legal_UK = <!-- GSL / P / POM / CD --> | |||
| legal_US = <!-- OTC / Rx-only --> | |||
{{ | <!--Identifiers--> | ||
| | | CASNo_Ref = {{cascite|correct|CAS}} | ||
| | | CAS_number_Ref = {{cascite|correct|??}} | ||
|CAS_number=10596-23-3 | | CAS_number = 10596-23-3 | ||
|ATC_prefix=M05 | | ATC_prefix = M05 | ||
|ATC_suffix=BA02 | | ATC_suffix = BA02 | ||
| | | PubChem = 25419 | ||
| | | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | ||
|DrugBank= | | DrugBank = DB00720 | ||
| | | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ||
| | | ChemSpiderID = 23731 | ||
| | | UNII_Ref = {{fdacite|correct|FDA}} | ||
| | | UNII = 0813BZ6866 | ||
| | | KEGG_Ref = {{keggcite|correct|kegg}} | ||
| | | KEGG = D03545 | ||
| | | ChEBI_Ref = {{ebicite|correct|EBI}} | ||
| | | ChEBI = 110423 | ||
| | | ChEMBL_Ref = {{ebicite|correct|EBI}} | ||
| | | ChEMBL = 12318 | ||
| | |||
| | <!--Chemical data--> | ||
| | | C=1 | H=4 | Cl=2 | O=6 | P=2 | ||
| | | molecular_weight = 244.892 g/mol | ||
| | | smiles = ClC(Cl)(P(=O)(O)O)P(=O)(O)O | ||
| InChI = 1/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9) | |||
| InChIKey = ACSIXWWBWUQEHA-UHFFFAOYAO | |||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChI = 1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9) | |||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | |||
| StdInChIKey = ACSIXWWBWUQEHA-UHFFFAOYSA-N | |||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
''' | {{CMG}} | ||
==Overview== | |||
'''Clodronic acid''' ([[International Nonproprietary Name|INN]]) or '''clodronate disodium''' ([[United States Adopted Name|USAN]]) is a first generation (non-nitrogenous) [[bisphosphonate]]. It is an anti-osteoporotic drug approved for the prevention and treatment of osteoporosis in post-menopausal women and men to reduce vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma and fracture related pain because of its potent anti-inflammatory and analgesic effects shown as a reduction in inflammatory markers like IL-1β, IL-6, and TNF-alfa. | |||
An Italian study compared the analgesic effect of clodronic acid versus [[acetaminophen]] in reumatic condition related pain. Study result show a reduction in pain in favor of clodronic acid that provided more analgesia than 3 grams/day of acetaminophen. Clodronate is also used in experimental medicine to selectively deplete [[macrophages]]. | |||
Clodronic acid is approved for human use in Canada and Australia, the United Kingdom, where it is marketed as Bonefos, Loron, Clodron and in Italy as Clasteon, Difosfonal, Osteostab and several generics. In other countries is prescribed as a bone resorption inhibitor and antihypercalcemic agent. | |||
==Use in equine medicine== | |||
Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of [[navicular syndrome]]. It is given by intramuscular injection, with the total dose divided into 3 sites on the horse. Clinical effects may not be seen for up to 2 months, and horses may need treatments repeated every 3 to 6 months. | |||
===Adverse reactions and contraindications=== | |||
Osphos has been shown to have several adverse effects. These include: | |||
* Signs of discomfort, agitation, or [[horse colic|colic]], usually within 2 hours of treatment. | |||
* Head shaking | |||
* Lip licking | |||
==References== | |||
{{Reflist|2}} | |||
{{Bisphosphonates}} | {{Bisphosphonates}} | ||
[[Category:Bisphosphonates]] | [[Category:Bisphosphonates]] | ||
[[Category: | [[Category:Drug]] | ||
Latest revision as of 15:37, 10 April 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | CH4Cl2O6P2 |
Molar mass | 244.892 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Clodronate |
Articles |
---|
Most recent articles on Clodronate |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Clodronate at Clinical Trials.gov Clinical Trials on Clodronate at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Clodronate
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Clodronate Discussion groups on Clodronate Patient Handouts on Clodronate Directions to Hospitals Treating Clodronate Risk calculators and risk factors for Clodronate
|
Healthcare Provider Resources |
Causes & Risk Factors for Clodronate |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Clodronic acid (INN) or clodronate disodium (USAN) is a first generation (non-nitrogenous) bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment of osteoporosis in post-menopausal women and men to reduce vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma and fracture related pain because of its potent anti-inflammatory and analgesic effects shown as a reduction in inflammatory markers like IL-1β, IL-6, and TNF-alfa.
An Italian study compared the analgesic effect of clodronic acid versus acetaminophen in reumatic condition related pain. Study result show a reduction in pain in favor of clodronic acid that provided more analgesia than 3 grams/day of acetaminophen. Clodronate is also used in experimental medicine to selectively deplete macrophages.
Clodronic acid is approved for human use in Canada and Australia, the United Kingdom, where it is marketed as Bonefos, Loron, Clodron and in Italy as Clasteon, Difosfonal, Osteostab and several generics. In other countries is prescribed as a bone resorption inhibitor and antihypercalcemic agent.
Use in equine medicine
Clodronic acid is approved for use in horses under the trade name Osphos, for treatment of navicular syndrome. It is given by intramuscular injection, with the total dose divided into 3 sites on the horse. Clinical effects may not be seen for up to 2 months, and horses may need treatments repeated every 3 to 6 months.
Adverse reactions and contraindications
Osphos has been shown to have several adverse effects. These include:
- Signs of discomfort, agitation, or colic, usually within 2 hours of treatment.
- Head shaking
- Lip licking